Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice

Hibino, Yuto; Fujisawa, Shin; Fujimaki, Katsumichi; Hagihara, Maki; Fujita, Hiroyuki; Tanaka, Masatsugu; Takayama, Kosuke; Takeda, Takaaki; Matsumura, Ayako; Suzuki, Taisei; Ishii, Yoshimi; Nakajima, Yuki; Miyazaki, Takuya; Nakajima, Hideaki

doi:10.1016/j.leukres.2025.107689

Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice

The prognosis of chronic myeloid leukemia has significantly improved with the introduction of tyrosine kinase inhibitors (TKIs). However, indefinite TKI treatment can lead to adverse effects and high costs. Recent studies have suggested that treatment-free remission (TFR) is achievable in patient…